Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials
Authors' conclusion
Semaglutide shows notable and consistent efficacy in reducing HbA1c and BW across all age subgroups with T2D, including young adults.
Study context
- Population
- Adults with T2D in the SUSTAIN (once-weekly subcutaneous) and PIONEER (once-daily oral) semaglutide programmes
- Comparison
- Semaglutide vs placebo and active comparators, by age subgroup
- Primary endpoint
- Change in HbA1c and BW by age subgroup
Methodological detailsage subgroup analysis
- Age subgroup analysis
Primary result
As reported in the abstract
Change in HbA1c and BW with semaglutide by age subgroup
- Reduction in HbA1c and body weight (BW) with semaglutide across all age subgroups, particularly in young adults vs other age subgroups
- Post hoc analysis
Safety
- Proportion with serious adverse events (SAEs) overall comparable between semaglutide and comparators across age subgroups and administration route
Original publication
Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials. Diabetes Obes Metab. Published 17 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →